Diabetes mellitus (DM) is a important health problem that induces ernestful complications
and it causes significant morbidity owing to specific microvascular complications such as …

Background Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age
population worldwide. Many observational and preclinical studies have implicated vascular …

OBJECTIVE The expression of vascular endothelial growth factor (VEGF) is elevated in
diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants …

Diabetic macular edema (DME), defined as a retinal thickening involving or approaching the
center of the macula, represents the most common cause of vision loss in patients affected …

In the past years, the management of diabetic retinopathy (DR) relied primarily on a good
systemic control of diabetes mellitus, and as soon as the severity of the vascular lesions …

Objectives The aim of this systematic review is to appraise the evidence for the use of anti-
VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best …

Background: Intravitreal ranibizumab and pegaptanib are registered for neovascular age-
related macular degeneration. No formal safety study has been conducted for intravitreal …

Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness in the
working-age population. The identification of vascular endothelial growth factor (VEGF) as a …

Aims To examine possible benefits of intravitreal bevacizumab (IVB) pretreatment in
vitrectomy for severe diabetic retinopathy. Methods A comprehensive literature search was …

Purpose: To compare the concentration of unbound bevacizumab in the anterior chamber of
patients with macular edema, who received a single intravitreal injection of two different …